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Upon noxious insults, cells of the brain parenchyma activate endogenous self-protective
mechanisms to counteract brain damage. Interplay between microglia and astrocytes can
be determinant to build a physiological response to noxious stimuli arisen from injury
or stress, thus understanding the cross talk between microglia and astrocytes would
be helpful to elucidate the role of glial cells in endogenous protective mechanisms and
might contribute to the development of new strategy to mobilize such program and
reduce brain cell death. Here we demonstrate that chemokines CX3CL1 and CXCL16
are molecular players that synergistically drive cross-talk between neurons, microglia and
astrocytes to promote physiological neuroprotective mechanisms that counteract neuronal
cell death due to ischemic and excitotoxic insults. In an in vivo model of permanent
middle cerebral artery occlusion (pMCAO) we found that exogenous administration of
soluble CXCL16 reduces ischemic volume and that, upon pMCAO, endogenous CXCL16
signaling restrains brain damage, being ischemic volume reduced in mice that lack CXCL16
receptor. We demonstrated that CX3CL1, acting on microglia, elicits CXCL16 release from
glia and this is important to induce neroprotection since lack of CXCL16 signaling impairs
CX3CL1 neuroprotection against both in vitro Glu-excitotoxic insult and pMCAO. Moreover
the activity of adenosine receptor A3R and the astrocytic release of CCL2 play also a
role in trasmembrane chemokine neuroprotective effect, since their inactivation reduces
CX3CL1- and CXCL16 induced neuroprotection.
Keywords: CX3CL1, CXCL16, CCL2, A3R, glia cross-talk, neuroprotection, ischemia, excitotoxicity
INTRODUCTION
Glial cells, able to sense changes in brain environment, represent
active players in various pathological conditions such as chronic
neurodegenerative disease, trauma and stroke. It is now estab-
lished that both microglia and astrocytes can play dual roles in the
CNS having either detrimental or beneficial effects participating
and enhancing inflammatory conditions, or limiting neuroin-
flammation, favoring repair and enhancing neuronal survival (Liu
et al., 2011). Thus understanding the cross talk between microglia
and astrocytes would be helpful to elucidate the role of glial cells
in pathological conditions.
Microglia-astrocytes interplay is granted by different types
of soluble mediators including ATP, adenosine, glutamate (Glu)
(Boison et al., 2010; Burnstock et al., 2011; Franke et al., 2012;
Pascual et al., 2012), growth factors and inflammatory cytokines
(Hamby and Sofroniew, 2010). We have recently shown that the
transmembrane chemokine CXCL16 and its receptor, CXCR6, are
constitutively expressed in glia and neurons being able to drive
neuroprotection against Glu excitotoxicity and oxygen glucose
deprivation (OGD) insults in culture (Rosito et al., 2012). In
particular we found that the neuroprotective activity of CXCL16
involves astrocytic release of CCL2 and the synergistic activity of
adenosine and adenosine type 3 receptor (A3R) on astrocytes.
The other known trasmembrane chemokine CX3CL1 is con-
stitutively expressed in the brain only by neurons, while its
unique receptor CX3CR1 is exclusively present on microglial
cells. Recently described as a neuronal “off signal” that keep
microglia in resting state (Biber et al., 2007), in the last decade
the role of CX3CL1-CX3CR1 signaling in modulating neuron
viability has emerged in several studies on neurodegenerative and
neuroinflammatory disease models (Soriano et al., 2002; Cardona
et al., 2006; Huang et al., 2006; Dénes et al., 2008; Bhaskar
et al., 2010; Fuhrmann et al., 2010; Lee et al., 2010; Cipriani
et al., 2011). Moreover CX3CL1 ability to preserve neurons from
excitotoxic insult has been shown both in vitro and in vivo: in
particular CX3CL1 signaling in microglia determines the release
of soluble factors, such as adenosine that, acting on the adenosine
receptor type 1 (A1R), concur to neuroprotection against Glu
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excitotoxicity and cerebral ischemia (Limatola et al., 2005; Lauro
et al., 2010; Cipriani et al., 2011; Catalano et al., 2013).
In the present paper we studied the interplay between
trasmembrane chemokines and between glial cells in determin-
ing neuroprotection against excitotoxic insults. In particular we
found that: (i) CXCL16 is able to reduce ischemic brain vol-
ume; (ii) following ischemic insults there is an overexpression
of CXCL16; (iii) CXCL16 and CCL2 are released from glia
upon CX3CL1 stimulation; and (iv) A3R and CXCR6 concur to
CX3CL1 mediated neuroprotection.
MATERIALS AND METHODS
ANIMALS
Procedures using laboratory animals were in accordance with
the international guidelines on the ethical use of animals from
the European Communities Council Directive of 24 November
1986 (86/609/EEC). C57BL/6J (wt) and homozygous cxcr6gfp/gfp
knock-in mice (Unutmaz et al., 2000) in which the coding region
of the receptor has been substituted with the coding region
of the Green Fluorescent Protein (GFP) were obtained from
Jackson Laboratory (strain name B6.129P2-Cxcr6tm1Litt/J). A3R
knockout mice (A3R−/−) (Salvatore et al., 2000) were also used.
Animals of either sex were used.
PERMANENT MIDDLE CEREBRAL ARTERY OCCLUSION (pMCAO)
Male mice (25–28 g, 10–12 weeks) were anesthetized with
intraperitoneal Equitensine at 3.5 ml/kg (39 mM pentobarbital,
256 mM chloral hydrate, 86 mM MgSO4, 10% ethanol v/v, and
39.6% propyleneglycol v/v). The right MCA was permanently
occluded by electrocoagulation as described previously (Storini
et al., 2006). Mice were maintained at 37◦C during surgery and
sacrificed 24 h after pMCAO.
INTRACEREBROVENTRICUL (I.C.V.) INJECTION
Recombinant mouse CXCL16 or mouse CX3CL1 (Peprotech) was
dissolved in saline solution and intracerebroventricularly injected
30 min before pMCAO. For dose-response experiments, mice
were injected with 15, 70 and 150 pmol CXCL16/2 µl. Anes-
thetized animals were immobilized on a stereotaxic apparatus
(David Kopf Instruments) and injected in the right cerebral
ventricle (1 mm lateral and 3 mm deep, according to the atlas
of Paxinos and Franklin, 2004). A constant rate of infusion
(0.2 µl/min) was maintained with a pump (KD Scientific).
BRAIN ISCHEMIC VOLUME MEASUREMENT
The extent of ischemic area was evaluated 24 h after ischemia.
Mice were deeply anesthetized with Equitensine and tran-
scardially perfused with ice-cold PBS (20 ml), pH 7.4, and
paraformaldehyde (PFA; 4%, 50 ml) in PBS. The brains were
carefully removed from the skull and transferred in 4% PFA at
4◦C overnight, then to PBS/30% sucrose at 4◦C overnight, frozen
in isopentane at−45◦C for 3 min, and then stored at−80◦C until
use. Twenty µm coronal brain cryosections were cut serially at
320 µm intervals and stained with cresyl violet. Infarct volumes
were calculated by integration of the infarct areas on each brain
slice, as described previously (Storini et al., 2006).
PRIMARY HIPPOCAMPAL CULTURES
Primary hippocampal cultures were prepared from the brain
of 0–2-day-old wild type (wt), cxcr6gfp/gfp and A3R−/− mice.
In brief, after careful dissection from diencephalic structures,
the meninges were removed and the hippocampi chopped and
digested in 0.025% trypsin, in Hank’s balanced salt solution
(HBSS) for 20 min at 37◦C. Cells were mechanically dissociated
and plated at a density of 2.5× 105 in poly-L-lysine coated plastic
24-well dishes, in serum-free Neurobasal medium supplemented
with B27, 0.5 mM L-glutamine and 100 µg/ml gentamicin. Suc-
cessively, cells were kept at 37◦C in 5% CO2 for 10–11 days in vitro
(DIV) with a twice a week medium replacement (1:1 ratio). With
this method we obtained 60–70% neurons, 30–35% astrocytes,
4–5% microglia, as determined with β-tubulin III, glial fibrillary
acidic protein (GFAP), and isolectin IB4 staining (Lauro et al.,
2010).
OXYGEN GLUCOSE DEPRIVATION (OGD)
Primary hippocampal cultures (10–11 DIV) were exposed to
OGD. Briefly, culture medium was replaced with modified Locke’s
buffer (without glucose), bubbled with 95% N2/5% CO2, and
transferred into an anaerobic chamber (Billups-Rothenberg MIC-
101) containing a mixture of 95% N2/5% CO2, and humidi-
fied at 37◦C for 90 min. For the reperfusion conditions OGD
was terminated by replacing the OGD medium with the orig-
inal conditioned medium. For comparative purposes, control
cultures were treated under normoxic conditions (95% O2/5%
CO2) in complete Locke’s buffer supplemented with glucose
(5.6 mM).
GLU EXCITOTOXICITY
In primary hippocampal cultures (10–11 DIV) conditioned
medium was removed and stored for later usage; neurons were
washed and stimulated with Glu (100 µM, 30 min) in modified
Locke’s buffer (without MgCl2 plus 1 µM glycine to stimulate
all types of Glu receptors), in the presence or in the absence of
recombinant mouse mCX3CL1 (100 nM, Peprotech). Under these
experimental conditions, only neurons die (Chen et al., 2000;
Rosito et al., 2012). After treatment, cells were re-incubated in
the original conditioned medium for 18–20 h, treated with lysis
buffer (0.5% ethylhexadecyldimethylammonium bromide, 0.28%
acetic acid, 0.5% Triton X-100, 3 mM NaC1, 2 mM MgCl, in
PBS pH 7.4) and counted in a hemocytometer for viability, as
described (Volontè et al., 1994). Data were expressed as percentage
of viable cells taking as 100% the number of viable cells in control
cultures. Variability in the number of viable cells in control
conditions never exceeded 10%.When necessary, cells were pre-
treated with monoclonal mouse αCCL2 Ab (3 µg/ml, 30 min;
R&D MAB479), rat IgG (3 µg/ml, 30 min; Santa Cruz Biotecnol-
ogy sc-2032), 3-propyl-6-ethyl-5-[(ethylthio)carbonyl]-2phenyl-
4-propyl-3-pyrinide carboxylate (MRS1523; 100 nM, Sigma) in
culture medium; drugs were present also during and after Glu
challenge.
RNA EXTRACTION AND ANALYSIS
Total RNA from ipsilateral (ischemic core and penumbra) and
controlateral (corresponding areas) brain emispheres of pMCAO
Frontiers in Cellular Neuroscience www.frontiersin.org July 2014 | Volume 8 | Article 193 | 2
Rosito et al. Chemokines interplay restrain brain damage
mice, from primary hippocampal mixed cell cultures (5 ×
105 cells), from primary astrocytes (2.5 × 105) and microglial
cells (2.5 × 105), was extracted by the use of Trizol reagent
(Invitrogen). Reverse transcription reaction was performed in a
thermocycler (MJ Mini Personal Thermal Cycler; Biorad) using
IScriptTM Reverse Transcription Supermix (Biorad) according
to the manufacturer’s protocol. Real-time PCR (RT-PCR) was
carried out in a I-Cycler IQ Multicolor RT-PCR Detection
System (Biorad) using SsoFast EvaGreen Supermix (Biorad)
according to the manufacturer’s instructions. The PCR protocol
consisted of 40 cycles of denaturation at 95◦C for 30 s and
annealing/extension at 58◦C for 30 s. For quantification analysis
the comparative Threshold Cycle (Ct) method was used. The Ct
values from each gene were normalized to the Ct value of β-actin
or GAPDH in the same RNA samples. Relative quantification was
performed using the 2−∆∆Ct method (Schmittgen and Livak,
2008) and expressed as fold change in arbitrary values. Primer
sequences targeted against CXCL16 (BC019961.1, GenBank),
mouse β-actin and GAPDH were as follows: CXCL16-forw.
TCCTTTTCTTGTTGGCGCTG, CXCL16rev. CAGCGACACT-
GCCCCTGGT; β-actin-forw.AGAGGGAAATCGTGCGTGAC,
β-actin-rev. CAATAGTGATGACCTGGCCGT; GAPDH-
forw. TCGTCCCGTAGACAAAATGG, GAPDH-rev.
CAAGGGGTTGAAGCTCAGAT.
GLIAL PRIMARY CULTURES
Primary cortical glial cells were prepared from 0–2-day-old wt
mice. Cerebral cortices were chopped and digested in 30 U/ml
papain for 40 min at 37◦C followed by gentle trituration. The
dissociated cells were washed, suspended in DMEM with 10%
fetal bovine serum (FBS; Gibco) and 2 mM L-glutamine and
plated at a density of 9–10 × 105 in 175 cm2 cell culture flasks.
At confluence (10–14 DIV), glial cells were shaken for 2 h at 37◦C
to detach and collect microglial cells. Astrocytes which remained
attached to the bottom of the flask were treated with trypsin
and collected. These procedures gave almost pure (no more
than 2% astrocyte contamination) microglial cell population, and
astrocytes cell population (4–6% of microglia contamination), as
verified by staining with GFAP and isolectin IB4.
MICROGLIA-ASTROCYTE CO-CULTURES
After 10–14 DIV, 8 × 105 microglial cells were re-plated and
co-cultured for 48 h with astrocytes cells (8 × 105) seeded on
24 mm transwell cell-culture inserts (pore size 0.4 µm; Corning
Life Sciences) which allows traffic of small diffusible substances,
but prevents cell contact. After co-cultures, cells were treated
with vehicle or soluble CX3CL1 (100 nM) for 18 h and upon
stimulation proteins from cells and conditioned medium was
collected and analyzed for Western blot. For CCL2 ELISA and
mRNA analysis 2.5 × 105 astrocyte were re-plated on 12 mm
transwell cell-culture inserts (pore size 0.4 µm; Corning Life
Sciences) and co-cultured with 2.5 × 105 microglial cells. After
48 h cells were treated with vehicle or soluble CX3CL1 (100 nM)
for 18 h. For ELISA conditioned medium (c.m.) was collected and
analyzed according to the manufacturer (R&D Systems), while for
mRNA extraction microglia and astrocytes were collected from
the different transwell compartments.
PROTEINS PREPARATION
C.m. from microglia-astrocytes co-cultures were collected and
concentrated by ultrafiltering on Ym-10 membrane (Centricon;
Millipore). For cell membrane proteins preparation, cells were
washed with phosphate-buffered saline and lysed for 15 min on
ice in hypotonic buffer containing 10 mM HEPES pH 8, 1.5 mM
MgCl2, 1 mM DDT, 1 µg/ml leupeptin, 1 µg/ml aprotinin,
and 1 mM phenylmethylsulfonyl fluoride. After centrifugation at
1500 rpm for 5 min at 4◦C, supernatant were ultra-centrifuged at
55000 rpm for 60 min, 4◦C, and pellet were suspended in NaCl
10 mM.
WESTERN BLOT ANALYSIS
Protein samples were separated on 10% SDS-polyacrylamide gel
and analyzed by Western immunoblot using a mouse CXCL16
antibody (0.2 µg/ml; R&D System, AF503) and HRP-tagged
rabbit anti goat IgG secondary antibody (1:2000; Dako), and sub-
sequently detected using a commercial chemiluminescent assay
(Immun-Star WesternC Kit; Bio-Rad). Densitometric analysis
was performed with Quantity One software (Biorad). Interpre-
tation of western-blot bands for CXCL16 was according to Gough
et al. (2004).
STATISTICAL ANALYSIS
The data are expressed as the means ± SEM. Where appropriate
t-test, or analysis of variance (ANOVA) was used: we performed
the parametric one-way ANOVA or two-way ANOVA followed
by specific multiple comparison, as described in detail in figure
legends. A value of p < 0.05 was considered significant. All
statistical analysis was done using SigmaPlot 11.0 Software.
RESULTS
SOLUBLE CXCL16 REDUCES THE ISCHEMIC VOLUME IN
MOUSE BRAIN AFTER pMCAO
Since we have recently demonstrated that CXCL16 is neuropro-
tective against Glu excitotoxicity in vitro (Rosito et al., 2012), we
now investigated the ability of CXCL16 to induce neuroprotection
in mice upon pMCAO. In wt mice, i.c.v. injection of soluble
CXCL16, 30 min before induction of pMCAO, resulted in a
decreased ischemic volume compared to wt mice injected with
saline (n = 10) control solution: in particular, a significant reduc-
tion in ischemic volume was observed after injection of 70 and
150 pmol of CXCL16 (n = 4–8; p < 0.05), while no effect was
observed upon injection of 15 pmol (n = 4; Figure 1A). Further
experiments were performed at 70 pmol. The neuroprotective
effect of CXCL16 was specific, being absent in mice that lack
CXCR6 receptor (cxcr6gfp/gfp mice; Figure 1B). Two-way ANOVA
analysis indicated a significant interaction between genotypes
and treatments (p = 0.02) and post hoc evaluation revealed
that CXCL16 was ineffective in reducing ischemic volume in
cxcr6gfp/gfp mice (n = 6). In addition, in cxcr6gfp/gfp mice, pMCAO
induced a significantly increased ischemic volume compared to
wt animals suggesting that endogenous CXCL16-CXCR6 sig-
naling contributes to restrain brain damage following ischemic
insult.
To investigate whether the protective effect of CXCL16 upon
pMCAO requires the activity of A3R, we analyzed the effect
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FIGURE 1 | CXCL16 reduces ischemic volume in pMCAO. (A) CXCL16
dose-response effect. Left: Mice were i.c.v. injected with saline or CXCL16
(15–70-150 pmol) 30 min before pMCAO and analyzed for ischemic volume
24 h later (n = 4–10). Right: representative brain coronal sections from
saline and CXCL16 i.c.v injected mice. Pale demarcated areas depict the
ischemic lesions. (B) CXCL16 effect in wt, cxcr6 gfp/gfp , and A3R−/− mice.
Mice of different genotypes (as indicated) were injected with saline or
CXCL16 (70 pmol) before pMCAO and analyzed for ischemic volume (n =
6–10). Representative brain coronal section of pMCAO saline injected mice
of different genotypes (Bottom). Results represent the mean ± SEM.
Statistical analysis: one-way ANOVA followed by Holm-Sidak post-hoc test
*p < 0.05 (A). Two-way ANOVA followed by Holm-Sidak post-hoc test
* p < 0.05; ** p < 0.001; * refers to wt-A3R−/−comparison; # p < 0.05
refers to wt-cxcr6gfp/gfp comparison (B).
of i.c.v. administration of CXCL16 in A3R−/− mice (n = 6–
7; Figure 1B). Two-way ANOVA analysis reveals a significant
differences between genotypes (p < 0.001), being the ischemic
volume higher in A3R−/− vs. wt animals. CXCL16 administration
was effective in reducing ischemic volume in both genotypes,
(p < 0.05) but the reduction observed in A3R−/− mice was less
pronounced (12.3% in A3R−/− vs. 26.3 % in wt).
ISCHEMIC INSULTS INDUCE UP-REGULATION OF
ENDOGENOUS CXCL16
Since CXCL16 signaling is determinant in reducing brain damage,
we measured CXCL16 expression in the brain upon ischemia.
RT-PCR analysis revealed that 24 h after pMCAO CXCL16 mRNA
specifically increased in the ipsilateral hemisphere (n = 5; p <
0.001; Figure 2A), while no differences were observed in sham
operated mice (not shown). Similar results were obtained in vitro,
when hippocampal cultures were treated to induce OGD cell
death (Rosito et al., 2012). After 90 min of OGD we observed a
reduction of CXCL16 mRNA, followed by a significant increase
after 2 h of recovery (n = 8–11; p< 0.05; Figure 2B).
CXCL16 IS RELEASED FROMMICROGLIA AND ASTROCYTES UPON
CX3CL1 STIMULATION
To investigate if CXCL16 could be released from glia upon treat-
ment with the neuroprotective chemokine CX3CL1, conditioned
media (c.m.) from microglia/astrocytes co-cultures (in transwell
system, see Section Materials and Methods) treated or not with
CX3CL1 (100 nM, 18 h), were analyzed for CXCL16 presence.
Data shown in Figure 3A revealed a significant increase in soluble
CXCL16 upon CX3CL1 treatment (n = 12; p< 0.001). Membrane
fractions of both microglia and astrocytes were also analyzed
and we found that after CX3CL1 treatment the mature form of
CXCL16 was significantly increased (Figures 3B,C top panels;
n = 6; p < 0.05). Interestingly, we also observed an increased
expression of CXCL16 mRNA upon CX3CL1 stimulation both in
microglia and astrocytes (Figures 3B,C bottom panels; n= 6–8;
p< 0.05).
CXCL16 IS A MEDIATOR OF CX3CL1-INDUCED NEUROPROTECTION
AGAINST GLU EXCITOTOXICITY
Since CXCL16 acts on its unique receptor CXCR6, we per-
formed experiments on the neuroprotective activity of CX3CL1
against Glu excitotoxicity in hippocampal cultures obtained
from cxcr6gfp/gfp mice, to investigate the possible involvement
of CXCL16 in CX3CL1-induced neuroprotection. As reported in
Figure 4, CX3CL1 was less effective in preventing cell death in
hippocampal cultures derived from mice that lack CXCL16 signal-
ing, compared with wt cultures. In particular, statistical analysis
(two-way ANOVA) indicated a significant interaction between
genotypes and treatment, with a main effect of treatments (p =
0.004). In cxcr6gfp/gfp mice, a significant difference between Glu
and both control and Glu/CX3CL1 treated cells was observed
(n = 8–10; p< 0.05).
THE MEDIATORS OF CXCL16 NEUROPROTECTIVE ACTIVITY ARE
ACTIVE PLAYERS IN CX3CL1 NEUROPROTECTION
The activity of CXCL16 and A3R on astrocytes and the con-
sequential release of CCL2 are key events in CXCL16 induced
neuroprotection (Rosito et al., 2012). To further corroborate
the CX3CL1-CXCL16 connection in neuroprotection, we ana-
lyzed the contribution of A3R and CCL2 in this mechanism.
We performed excitotoxic experiments in hippocampal cultures
derived from A3R−/− mice: at difference with wt, in A3R−/−
cultures CX3CL1 was less effective in preventing cell death
(Figure 5A). Statistical analysis (two-way ANOVA) indicated a
significant interaction between genotypes and treatment (p =
0.025), with a main effect of treatments. Both in wt and A3R−/−
animals, a significant difference between Glu and both control
and Glu/CX3CL1 treated cells was observed (post hoc analysis,
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FIGURE 2 | CXCL16 expression is increased upon ischemic insults. (A)
CXCL16 mRNA quantification in pMCAO brain. qRT-PCR analysis in
contralateral and ipsilateral emisphere 24 h after pMCAO (n = 5). (B) CXCL16
mRNA quantification in in vitro OGD. qRT-PCR analysis in primary hippocampal
cultures after 90 min of OGD (n = 11) and after 2 h of recovery (n = 8). Data
are expressed as mRNA fold increase normalized to β-actin. Results represent
the mean ± SEM. Statistical analysis: Student’s t-test ** p < 0.001 (A);
one-way ANOVA followed by Dunn’s post-hoc test * p < 0.05 (B).
FIGURE 3 | Glial cells increase CXCL16 expression upon CX3CL1
stimulation. (A) CX3CL1 induces the release of soluble CXCL16 from glial
cells. Western-blot analysis for CXCL16 protein in the conditioned medium
(c.m.) of astrocytes-microglia co-cultures stimulated or not with CX3CL1
(100 nM, 18 h). Representative blot is shown (n = 12). (B–C) CXCL16
up-regulation in microglia (B) and astrocytes (C) following CX3CL1
stimulation. Top: Western-blot analysis for mature and precursor (pre)
CXCL16 species (Gough et al., 2004) in unstimulated and stimulated cells
derived from co-cultures experiments. Representative blots are shown (n =
6). Bottom: qRT-PCR analysis for CXCL16 mRNA expression in microglia (B)
and astrocytes (C) derived from co-cultures experiments treated or not
with CX3CL1 for 4, 8, 18 h (n = 8). Data are expressed as mRNA fold
increase normalized to GAPDH. Results represent the mean ± SEM.
Statistical analysis: Student t-test * p < 0.05; ** p < 0.001 (A, B–C top
panels); one-way ANOVA followed by Dunn’s post hoc test (B–C) bottom
panels * p < 0.05.
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FIGURE 4 | CXCL16 contributes to CX3CL1 neuroprotection against Glu
toxic insult. Glu-excitotoxic experiments were performed in wt and cxcr6
gfp/gfp mice hippocampal cultures treated or not with CX3CL1 (n = 8–10).
Data are expressed as percentage of viable cells in treated cultures taking
as 100% the number of viable cells in wt control condition. Results
represent the mean ± SEM. Statistical analysis: two-way ANOVA followed
by Dunn’n post-hoc test * p < 0.05.
n = 6; p < 0.05). According to this result, the A3R inhibitor
MRS1523 reduced CX3CL1 neuroprotection (n = 5; p < 0.05;
Figure 5B). Moreover, as reported in Figure 5C in the presence
of neutralizing αCCL2 Ab (but not with control IgG, both used at
3 µg/ml), CX3CL1 was not able to induce neuroprotection (n =
4; p< 0.05).
To verify the hypothesis that CX3CL1 could also induce the
release of CCL2, that concur to neuroprotection, we stimulated
microglia-astrocytes co-cultures or microglia with CX3CL1 for
18 h and measured CCL2 level in the c.m. Figure 5D shows a
basal release of CCL2 that increases upon CX3CL1 stimulation
in microglia-astrocyte co-culture (n = 11; p < 0.001 Rank sum
Test) but not in microglia alone (n = 7; p = 0.7 Rank sum Test),
suggesting that CX3CL1 acting on microglia, induces the release
of CCL2 from astrocytes.
CX3CL1 NEUROPROTECTION AGAINST pMCAO IS REDUCED IN
cxcr6gfp/gfp MICE
CX3CL1 is neuroprotective in pMCAO (Cipriani et al., 2011). To
further confirm that CXCL16 contributes to CX3CL1 neuropro-
tection, wt and cxcr6gfp/gfp mice were i.c.v. injected with soluble
CX3CL1, 30 min before induction of pMCAO: as reported in
Figure 6, two-way ANOVA analysis reveals a significant difference
between genotypes (p< 0.001), being the ischemic volume higher
in cxcr6gfp/gfp mice vs. wt animals. CX3CL1 administration was
effective in reducing ischemic volume in both genotypes (p <
0.05) but the reduction observed in cxcr6gfp/gfp mice was less
pronounced being 10.9% (n = 6) vs. 25.6 % in wt (n = 4).
DISCUSSION
Glial cells, long thought to act as a mere “support” network,
have been gaining increasing attention as crucial protagonists in a
variety of neural functions including information processing but
also cell viability. In the present paper we describe for the first time
the ability of trasmembrane chemokines CX3CL1 and CXCL16
to drive molecular interplay between neurons, microglia and
astrocytes in determining the neuroprotection against pMCAO
and excitotoxic damage, showing that a concerted action of these
cells is important to determine neuronal survival upon exposure
to high level of Glu, a condition that normally occurs following
ischemia (Castillo et al., 1996) but also in traumatic brain injuries
(Zauner et al., 1996) or chronic neurodegenerative diseases (Shaw
et al., 1995; Hallett and Standaert, 2004; Lipton, 2005).
In line with previous in vitro findings, we demonstrated
that exogenous administration of soluble CXCL16 reduced brain
ischemic volume following pMCAO; moreover we found that
upon ischemic insult CXCL16 expression is increased in the
ischemic hemisphere and that endogenous CXCL16 signaling is
important per se to counteract brain damage, since in cxcr6gfp/gfp
mice there is a significant increase in brain ischemic volume upon
pMCAO. All together, these data indicate that CXCL16 represents
a physiological mediator of self-protective mechanisms engaged
by brain parenchyma to restrain cell damage following toxic
insult. Upon brain ischemia, there is the simultaneous activation
of destructive pathways leading to cell death but also of local
protective mechanisms. Although the damaging effectors appar-
ently prevail, evidences suggest that concomitant self-protective
mechanisms might limit the resulting damage and set the stage for
tissue repair and reorganization (Moskowitz et al., 2010; Iadecola
and Anrather, 2011; Figure 7). Thus unveiling the molecular
players that act in self-protective mechanism might provide new
opportunity to treat brain pathologies.
Damaged neurons respond to neurotoxic insults releasing
soluble factors that can be sensed by surrounding glia: CX3CL1,
a chemokine selectively expressed by neurons in the nervous
system, is one of such mediators being upregulated (Tarozzo et al.,
2002; Zhu et al., 2009), cleaved and released upon ischemia and
excitotoxic insult (Chapman et al., 2000; Limatola et al., 2005;
Noda et al., 2011 ) and being able to drive neuroprotection
(Limatola et al., 2005; Lauro et al., 2010; Cipriani et al., 2011). We
reported here that, upon CX3CL1 stimulation, glial cells produce
and release CXCL16, important for CX3CL1 neuroprotective
effect. We speculate that CX3CL1 released from neurons upon
ischemia might drive microglia-astrocytes cross-talk leading to
CXCL16 increase. These data further corroborate the idea that,
although the only direct targets of CX3CL1 are microglial cells, its
neuroprotective effects are mediated by engagement of astrocytes
that concur to limit excitotoxic cell death with the synergistic
activity of adenosine (Catalano et al., 2013).
We do not know the mechanism that leads to the release
of CXCL16 from glia, however it has been recently reported
that activation of the purinergic receptor P2X7 induces CXCL16
shedding from RPMI8226 myeloma B cells (Pupovac et al.,
2013). Hippocampal cells stimulation with CX3CL1 induces an
increase in extracellular adenosine probably derived from released
ATP, the effect being specifically blocked by the treatment with
the ectonucleotidase inhibitor alpha-beta-methyleneadenosine
5′-diphosphate sodium salt (AOPCP) (Lauro et al., 2010). Since
both astrocytes and microglia express P2X7 receptors, it could be
hypothesized that CX3CL1 induces ATP release from microglia
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FIGURE 5 | A3R activity and astrocytic CCL2 concur to CX3CL1
neuroprotection. (A) Genetic deletion of A3R reduces CX3CL1
neuroprotection. Glu-excitotoxic experiments were performed in hippocampal
cells derived from wt or A3R−/− mice (n = 6). Data are expressed as
percentage of viable cells in treated cultures taking as 100% the number of
viable cells in wt control condition. (B) Pharmacological inhibition of A3R
reduces CX3CL1 neuroprotection. Primary hippocampal cells were treated
with A3R specific antagonists MRS1523 and used for Glu-excitotoxic
experiments (n = 5). Data are expressed as percentage of viable cells in
treated cultures taking as 100% the number of viable cells in vehicle control
condition. (C) Neutralization of CCL2 activity prevents CX3CL1
neuroprotection. Glu-excitotoxic experiment were performed in hippocampal
cultures in the presence of neutralizing αCCL2 Ab (3 µg/ml) or control IgG
(3µg/ml) (n = 4–6). Data are expressed as percentage of viable cells in treated
cultures taking as 100% the number of viable cells in IgG control condition.
(D) CX3CL1 triggers CCL2 release from astrocytes. Microglia-astrocytes
co-cultures or microglia alone were treated with CX3CL1or vehicle, and the
c.m. were collected after 18 h. CCL2 levels in the media were measured by
ELISA (n = 7–11). Results represent the mean ± SEM. Statistical analysis:
two-way ANOVA followed by Holm-Sidak post-hoc test * p < 0.05 (A);
one-way ANOVA followed by Holm-Sidak post-hoc test * p < 0.05 (B–C);
Student’s t-test ** p < 0.001 (D).
that, acting on P2X7 receptors, induces CXCL16 shedding from
surrounding glial cells. A role for P2X7 in the release of neuro-
protective mediators is in agreement with previous data showing
that P2X7 activation reduces excitotoxic neuronal death, through
TNF-α shedding from microglia (Suzuki et al., 2004).
Adenosine modulates neuron-glia communication (Boison
et al., 2010) and can mediate neuroprotective effects through
the activity of its own receptors: in this regards the activity of
A1R is crucial to allow neuroprotection driven by CX3CL1, IL-
6, oncostatin M (OSM), BDNF and erythropoietin (EPO) (Biber
et al., 2008; Lauro et al., 2010; Moidunny et al., 2010). Also A3R
activity can mediate neuroprotection since it has been shown
that hypoxic conditions determine a wider neurodegeneration in
A3R−/− mice (Fedorova et al., 2003) and i.c.v. injection of A3R
selective agonist in mice reduces brain ischemic volume (Chen
et al., 2006). In the present work, we confirmed an increased
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FIGURE 6 | CX3CL1 neuroprotection against pMCAO is reduced in
cxcr6 gfp/gfp mice. Mice were i.c.v. injected with saline or CX3CL1 (70
pmol) 30 min before pMCAO and analyzed for ischemic volume 24 h later
(n = 4–10). Results represent the mean ± SEM. Statistical analysis: two-way
ANOVA followed by Holm-Sidak post-hoc test * p < 0.05; ** p < 0.001.
ischemic volume in A3R−/− mice compared to wt mice and
found that the ability of CXCL16 to reduce ischemic volume is
less pronounced in these mice. This is in line with our previous
in vitro findings, where we have shown that soluble CXCL16 is
able to promote neuronal survival against excitotoxic damage
depending on A3R activity (Rosito et al., 2012), and in particular
the synergistic activity of CXCL16 and A3R on astrocytes causes
the release of CCL2 that act as a key mediator of neuroprotection.
We speculate that upon ischemic insult, CXCL16 released from
glia concurs to endogenous neuroprotective mechanism elicited
by neuronal CX3CL1 since we found that CX3CL1-induced neu-
roprotection was reduced in cxcr6gfp/gfp mice; both genetic and
pharmacological inactivation of A3R reduces CX3CL1 neuropro-
tection against Glu excitotoxic insult; CX3CL1 is able to increase
the release of CCL2 from astrocytes; CCL2 activity is important
for CX3CL1 protective effect.
Nevertheless, our data showed that impairment of CXCL16
or A3R signaling in transgenic animals reduced, but did not
totally prevented CX3CL1 neuroprotection, indicating that the
mechanism we here proposed represent only a portion of the
neuroprotective mechanisms driven by CX3CL1.
The involvement of A1R in CX3CL1 neuroprotection (Lauro
et al., 2010) strongly suggests that there must be at least another
mechanism, independent from CXCL16, important to protect
cells from Glu excitoxicity: accordingly we have recently published
that the activity of Glu transporter GLT1 on astrocytes is increased
by CX3CL1, with mechanisms requiring A1R activation and this
event is also crucial for CX3CL1 neuroprotection (Catalano et al.,
2013).
In conclusion, the present work highlights the role played
by chemokines as key endogenous modulators of the cross-talk
FIGURE 7 | Endogenous self-protective mechanism drived by
CX3CL1–CXCL16-CCL2 upon ischemia. Ischemic insult drives irreversible
brain damage in ischemic core, while in the surrounding region (ischemic
penumbra) brain tissue results to be functionally compromised but
potentially “salvageable”. Upon ischemic insult both pathogenic and
self-protective mechanisms occur in the penumbra. CX3CL1-CXCL16-CCL2
cascade, triggered by neurons-microglia-astrocytes cross-talk, represents
one endogenous self-protective mechanism that contributes to the
restriction of brain damage by counteracting Glu induced excitotoxicity.
between cells of brain parenchyma, that drive physiological neu-
roprotective mechanisms. In particular we demonstrated the
existence of chemokine induced chemokine release (CX3CL1-
CXCL16-CCL2) mechanism that involves neurons, microglia
and astrocytes and that represents an endogenous self-protective
mechanism that upon brain ischemia can limit cell damage in the
ischemic penumbra, by counteracting neuronal cell death due to
Glu excitotoxicity (Figure 7).
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